Thursday, February 21, 2013

Why consumer watchdog agency still has no chief

Senate Republicans have vowed to block President Obama?s nomination of Richard Cordray to become director of the Consumer Financial Protection Bureau unless Congress takes steps that would weaken the agency.

In a recent letter to the White House, Senate Minority Leader Mitch McConnell, R-Ky., and 42 GOP colleagues said they will continue to oppose the consideration ?of any nominee, regardless of party affiliation? until changes are made to ?ensure accountability and transparency? at the CFPB.

Sen. McConnell said Republicans have ?serious concerns about the lack of congressional oversight of the agency and the lack of normal, democratic checks on its sole director, who would wield nearly unprecedented powers.?

Consumer groups and Democrats on Capitol Hill are outraged at what they believe is a blatant attempt to muzzle the consumer watchdog agency.

?They?re playing politics with the pocketbooks of the American people and the safety of our economy,? said consumer advocate Ed Mierzwinski of U.S. PIRG.

?Republicans are trying to dismantle the consumer protection bureau and put the power back in the hands of big corporations,? said Senate Majority Leader Harry Reid, D-Nev., in a statement. ?American consumers deserve a cop on the beat to advocate for their interests against reckless corporations and their armies of lawyers seeking to take advantage.?

The outcome of this power struggle will affect all Americans because the CFPB regulates the businesses that control so much of our financial lives, including banks, credit card issuers, mortgage lenders, debt collectors and credit reporting agencies.

In just 19 months, the agency has issued numerous rules designed to bring fairness and transparency to the financial marketplace. It has also levied record fines against some of the biggest financial companies in the country, resulting in $425 million being refunded to consumers.

What exactly do GOP lawmakers want?

Republicans say they want Congress to change the CFPB?s governance, funding and oversight before they will vote on a director for the agency.

  1. Governance: They want the CFPB to be run by a five-member bipartisan commission, rather than a director.
  2. Funding: They want the bureau to be subject to the annual appropriations process in Congress.
  3. Oversight: They want to make it easier for other federal banking regulators to veto any CFPB rule.

George Washington University law professor Arthur Wilmarth, Jr. wrote an analysis of the proposed changes in a paper titled: ?The Financial Services Industry?s Misguided Quest to Undermine the Consumer Financial Protection Bureau.? Here?s how he addressed the GOP?s proposed changes:

1. Governance

There are reasonable arguments on both sides as to whether the agency should be run by a director or a commission. While a single director increases accountability, a bipartisan commission might include a broader range of views. But the commission structure increases the possibility of deadlock if a single position is vacant.

Weighing all the factors ? efficiency, stability, decisiveness and accountability ? Prof. Wilmarth concluded that keeping a single-director makes the most sense.

2. Funding

Currently, the CFPB?s budget comes from the Federal Reserve and is capped at 12 percent of the Board?s budget each year.

If the CFPB does not have guaranteed funding and must seek Congressional budget approval each year, it is subject to Congressional whim and therefore pressure from business groups.

?The two agencies that don?t have assured funding ? the Securities and Exchange Commission and the Commodity Futures Trading Commission ? the industry strangles them through the appropriations process and makes them unable to accomplish their mission,? Wilmarth explained. ?Obviously, the industry wants this because they don?t want the CFPB to be effective.?

3. Oversight

The federal law that created the CFPB already defines and limits its regulatory powers. It establishes various layers of oversight. The agency reports to Congress (so far Corday has testified 30 times) and is watched by the General Accounting Office.

The CFPB ? unlike any other financial regulatory agency ? is also subject to review by the Financial Stability Oversight Council (FSOC) which can veto any bureau rule that?s shown to put ?the safety and soundness? of the U.S. banking system or the ?stability? of the U.S. financial system at risk.

Republicans want to give the FSOC the power to veto any CFPB rule that negatively impacts even a single bank or financial institution.

Wilmarth believes this would make it too easy to override CFPB actions and would give responsibility for consumer protection back to ?the same agencies that failed to protect both consumers and our financial markets during the past decade.?

Democrats go on the offensive

Three Democratic members of the Senate Banking Committee, Jack Reed of Rhode Island, Sherrod Brown of Ohio and Elizabeth Warren of Massachusetts, have called on their Republican colleagues to put Cordray?s nomination to an up-or-down vote.

Confirming a CFPB director would ?help consumers and strengthen our financial marketplace,? they said in a joint news release.

Sen. Warren knows more about this issue than most members of Congress. She?s the former Harvard professor who helped launch the CFPB in 2010 after it was created as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

She warned that this latest example of Congressional gridlock hurts everyone.

?Political stalemates don?t end in more government or less government, but in bad government ? government that lacks the clarity and predictability that our businesses need to plan for the future, to serve their customers, and to create jobs,? Warren said.

Herb Weisbaum is The ConsumerMan. Follow him on Facebook and Twitteror visit The ConsumerMan website.

Source: http://www.nbcnews.com/business/why-consumer-watchdog-agency-still-has-no-chief-1C8452387

courtney mercury retrograde bath salts heart shaped box lucid 2012 ncaa tournament bracket matterhorn

Novel coronavirus well-adapted to humans, susceptible to immunotherapy

Tuesday, February 19, 2013

The new coronavirus that has emerged in the Middle East is well-adapted to infecting humans but could potentially be treated with immunotherapy, according to a study to be published on February 19 in mBio?, the online open-access journal of the American Society for Microbiology. The study indicates that the virus HCoV-EMC can penetrate the lining of the passageways in the lung and evade the innate immune system as easily as a cold virus can, signs that HCoV-EMC is well-equipped for infecting human cells. The study also reveals that the virus is susceptible to treatment with interferons, components of the immune system that have been used successfully to treat other viral diseases, opening a possible mode of treatment in the event of a large-scale outbreak.

"Surprisingly, this coronavirus grows very efficiently on human epithelial cells," says co-author Volker Thiel of The Institute of Immunobiology at Kantonal Hospital in St. Gallen, Switzerland. Thiel says these new data indicate that although HCoV-EMC may have jumped from animals to humans very recently, it is just as well adapted to infecting the human respiratory tract as other, more familiar human coronaviruses, including the SARS virus and the common cold virus, HCoV-229E.

HCoV-EMC first came to light in June when it was isolated from a man in Saudi Arabia who died from a severe respiratory infection and kidney failure. Since that time, public health officials have identified an additional 10 infected persons, nine of whom had traveled in the Middle East and one who had recent contact with an infected person. The emergence of HCoV-EMC, which is related to the SARS virus, has raised concern that it may eventually lead to a pandemic much like the SARS pandemic of 2002-2003, which is estimated to have sickened over 8,000 people and killed 774 worldwide.

For the mBio? study, Thiel and his colleagues tested how well HCoV-EMC could infect and multiply in the entryways to the human lung using cultured bronchial cells manipulated to mimic the airway lining. The lining of the lung, or epithelium, represents an important first barrier against respiratory viruses, but they apparently don't put up a big fight against HCoV-EMC, says Thiel. He and his colleagues found that human airway epithelial cells are highly susceptible to HCoV-EMC infection and that the virus is able to multiply at a faster initial rate than the SARS virus.

"The other thing we found is that the viruses [HCoV-EMC, SARS, and the common cold virus] are all similar in terms of host responses: they don't provoke a huge innate immune response," Thiel says. This is an indication that HCoV-EMC is already well adapted to the human host and that the virus uses that same strategy other coronaviruses use for evading the host's non-specific immune mechanisms.

The authors asked themselves whether boosting this weak immune response might diminish the virus' ability to infect airway epithelial cells. They found that pre-treating the cells with lambda-type interferons, proteins that are released by host cells in response to infection and enable communication between cells to mount an immune response, significantly reduced the number of infected cells. This is encouraging from a treatment standpoint, note the authors, since interferons have also shown a good deal of promise for treating SARS and another viral illness, Hepatitis C.

Thiel and co-author Ronald Dijkman emphasize that their work with HCoV-EMC would not have been possible without the efforts of many different research groups from Switzerland, Germany, The Netherlands, and Denmark.

Ongoing collaboration is crucial, they say. Future research to head off outbreaks of HCoV-EMC and other emerging diseases requires cooperation and trust among scientists and health agencies, a goal that is not always achieved. The future of this virus is uncertain, Thiel points out, but access to samples from a wider range of patients and epidemiological work could answer some fundamental questions, including where the virus is coming from and what the true prevalence of the virus is.

"We don't know whether the cases we observe are the tip of the iceberg," says Thiel. "Or whether many more people are infected without showing severe symptoms."

###

American Society for Microbiology: http://www.asm.org

Thanks to American Society for Microbiology for this article.

This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.

This press release has been viewed 45 time(s).

Source: http://www.labspaces.net/126873/Novel_coronavirus_well_adapted_to_humans__susceptible_to_immunotherapy

AJ McCarron Johnny Manziel ups Aj Mccarron Girlfriend linkedin linkedin CES 2013

Wednesday, February 20, 2013

Experts split on Detroit's fiscal recovery options

DETROIT (AP) ? In less than a month, Michigan Gov. Rick Snyder will decide whether Detroit should get an emergency manager to oversee its financial recovery.

The question may not be who can save Detroit, but how can Detroit be saved.

Options are limited. Some experts are split on what may be best: long-term restructuring with state help or cutting the city's losses now through municipal bankruptcy.

National municipal bankruptcy expert James Spiotto says Detroit would be the largest city to file for Chapter 9 protection. He said that should be "the absolute last resort."

A review team said Tuesday that Detroit is in a financial emergency with more than $14 billion in long-term liabilities, a $327 million budget deficit and cash flow issues.

Source: http://news.yahoo.com/experts-split-detroits-fiscal-recovery-options-194221163.html

2012 draft colt mccoy arbor day mike adams janoris jenkins john edwards trial brandon weeden

'For Better or Worse' moves from TBS to OWN

LOS ANGELES (AP) ? Oprah Winfrey's cable channel says it will be the new home of the sitcom "For Better or Worse."

Tyler Perry's comedy series will move from TBS to OWN for its third season, starting this fall. OWN announced Wednesday that it's also getting rerun rights for the show's first two years.

"For Better or Worse" is about three couples dealing with the challenges of dating and married life. OWN says the original cast, including Tasha Smith and Michael Jai White, will remain with the show. Production on season three begins in April.

The comedy will be OWN's third scripted series from Perry, who has a deal with OWN to produce TV shows and other projects. The first two original series, a sitcom and a drama, are scheduled to debut in May.

Source: http://news.yahoo.com/better-worse-moves-tbs-own-224129122.html

dallas fort worth airport texas tornados seattle seahawks new uniforms wisconsin recall wisconsin recall doris day buffalo sabres

Tuesday, February 19, 2013

Uncapped paceman Kyle Abbott added to South Africa squad for the third Test agai...

Sorry, Readability was unable to parse this page for content.

Source: http://www.facebook.com/photo.php?fbid=10151726742859409&set=a.10150261923524409.377980.50014959408&type=1

American Music Awards 2012 oregon ducks oregon ducks rob gronkowski Coughing eddie murphy Stephanie Bongiovi

A solution to sinusitis from the sea

Feb. 18, 2013 ? A team of scientists and surgeons from Newcastle are developing a new nasal spray from a marine microbe to help clear chronic sinusitis.

They are using an enzyme isolated from a marine bacterium Bacillus licheniformis found on the surface of seaweed which the scientists at Newcastle University were originally researching for the purpose of cleaning the hulls of ships.

Publishing? recently in PLOS ONE, they describe how in many cases of chronic sinusitis the bacteria form a biofilm, a slimy protective barrier which can protect them from sprays or antibiotics. In vitro experiments showed that the enzyme, called NucB dispersed 58% of biofilms.

Dr Nicholas Jakubovics of Newcastle University said: "In effect, the enzyme breaks down the extracellular DNA, which is acting like a glue to hold the cells to the surface of the sinuses. In the lab, NucB cleared over half of the organisms we tested."

Sinusitis with or without polyps is one of the most common reasons people go to their GP and affects more than 10% of adults in the UK and Europe. Mr Mohamed Reda Elbadawey, Consultant of Otolaryngology Head and Neck Surgery, Freeman Hospital -- part of the Newcastle Hospitals NHS Foundation Trust -- was prompted to contact the Newcastle University researchers after a student patient mentioned a lecture on the discovery of NucB and they are now working together to explore its medical potential.

Mr Elbadawey said: "Sinusitis is all too common and a huge burden on the NHS. For many people, symptoms include a blocked nose, nasal discharge or congestion, recurrent headaches, loss of the sense of smell and facial pain. While steroid nasal sprays and antibiotics can help some people, for the patients I see, they have not been effective and these patients have to undergo the stress of surgery. If we can develop an alternative we could benefit thousands of patients a year."

In the research, the team collected mucous and sinus biopsy samples from 20 different patients and isolated between two and six different species of bacteria from each individual. 24 different strains were investigated in the laboratory and all produced biofilms containing significant amounts of extracellular DNA. Biofilms formed by 14 strains were disrupted by treatment with the novel bacterial deoxyribonuclease, NucB.

When under threat, bacteria shield themselves in a slimy protective barrier. This slimy layer, known as a biofilm, is made up of bacteria held together by a web of extracellular DNA which adheres the bacteria to each other and to a solid surface -- in this case in the lining of the sinuses. The biofilm protects the bacteria from attack by antibiotics and makes it very difficult to clear them from the sinuses.

In previous studies of the marine bacterium Bacillus licheniformis, Newcastle University scientists led by marine microbiologist Professor Grant Burgess found that when the bacteria want to move on, they release an enzyme which breaks down the external DNA, breaking up the biofilm and releasing the bacteria from the web. When the enzyme NucB was purified and added to other biofilms it quickly dissolved the slime exposing the bacterial cells, leaving them vulnerable.

The team's next step is to further test and develop the product and they are looking to set up collaboration with industry.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by Newcastle University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Robert C. Shields, Norehan Mokhtar, Michael Ford, Michael J. Hall, J. Grant Burgess, Mohamed Reda ElBadawey, Nicholas S. Jakubovics. Efficacy of a Marine Bacterial Nuclease against Biofilm Forming Microorganisms Isolated from Chronic Rhinosinusitis. PLOS ONE, 18 Feb 2013 DOI: 10.1371/journal.pone.0055339

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/~3/Hv0ViZJN4_Q/130218173302.htm

amazing race Cam Cameron Ada Lovelace 12/12/12 manny pacquiao Chopper Live jerry brown

Former WSU coach Raveling to receive HOF lifetime achievement award












by TRAVIS PITTMAN / KING 5 News

KING5.com

Posted on February 15, 2013 at 12:23 PM

Updated Friday, Feb 15 at 5:32 PM

Former Washington State University men?s basketball coach George Raveling was named the recipient of the 2013 John W. Bunn Lifetime Achievement Award by the Naismith Memorial Basketball Hall of Fame on Friday.

The award is considered the most prestigious honor the Hall can bestow, outside of enshrinement. The award honors those who have made outstanding accomplishments to impact the game of basketball.

?George was a trailblazer in the college coaching profession, he took so much pride in educating his players not only about basketball, but also about life,? said Jerry Colangelo, Chairman of the Hall of Fame board.

Raveling was an assistant for the Maryland Terrapins when they posted an undefeated season and a No. 1 national ranking in 1971.

In 1972, he moved to Pullman to coach the Cougars, back when the Pac-12 was still the Pac-8. In 11 seasons, he led the Cougs to a 167-136 record and two NCAA Tournament appearances. He also was the conference?s first African-American basketball coach.

Raveling would also coach at Iowa and USC, and he served as an assistant on the 1984 and 1988 U.S. Olympic teams.

Raveling retired in 1994 following a car crash that hospitalized him for several weeks with severe injuries. He became a color commentator for Fox Sports and CBS. He?s currently the Director of International Basketball for Nike.

Information compiled from the Naismith Memorial Basketball?Hall of Fame website.

?

Source: http://www.king5.com/sports/college/cougars/Former-WSU-coach-Raveling-to-receive-HOF-lifetime-achievement-award-191444461.html

911 masterchef Dictionary.com Chicago teachers strike september 11 2001 september 11 2001 blake lively